LG Life Sciences will target $500 million with its first domestic diabetes treatment ‘Zemiglo’

LG Life Sciences will speed up on expanding its first domestic diabetes treatment ‘Zemiglo (generic name: gemigliptin)’ to global markets.

According to the company, Zemiglo, launched on January 2013 after getting an approval in 2012, has grew more than twice up starting from KRW 6 billion at the launch to KRW 12.1 billion (KRW 14 billion if incluing Zemimet) in 2014. The goal of the product in...